$CVKD
Cadrenal Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Ponte Vedra, FL
CVKD chart
What traders are saying about $CVKD
Latest postsCadrenal Therapeutics, Inc. news
- Cadrenal Therapeutics, Inc. Estimates – NASDAQ:CVKD
TradingView ·
- Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Yahoo Finance ·
- Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Yahoo Finance ·
- Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Yahoo Finance ·
- Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Yahoo Finance ·
- CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
Yahoo Finance ·
- Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Yahoo Finance ·
- CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
Yahoo Finance ·
- Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
Yahoo Finance ·
- Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Yahoo Finance ·
- Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Yahoo Finance ·
- Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Yahoo Finance ·
Cadrenal Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M |
| Diluted EPS | $-6.64 | $-8.73 | $-9.29 | $-0.85 |
| Total assets (year end) | $4.3M | $10.1M | $8.5M | $778,174 |
| Cash and equivalents (year end) | $4.0M | $10.0M | $8.4M | $32,586 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Cadrenal Therapeutics, Inc.
- Ticker
- CVKD (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Ponte Vedra, FL
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1937993
Frequently asked questions
What exchange is Cadrenal Therapeutics, Inc. listed on?
Cadrenal Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CVKD.
What industry is Cadrenal Therapeutics, Inc. in?
Cadrenal Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Cadrenal Therapeutics, Inc. headquartered?
Cadrenal Therapeutics, Inc.'s business address on file with the SEC is in Ponte Vedra, FL.
When does Cadrenal Therapeutics, Inc.'s fiscal year end?
Cadrenal Therapeutics, Inc.'s fiscal year ends on December 31.